Citigroup Maintains Buy on Boston Scientific, Lowers Price Target to $61

Benzinga Newsdesk www.benzinga.com Negative 72.7%

Neg 72.7% Neu 0% Pos 0%

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $70 to $61.